Vol. 17/No. 14

Antoni Ribas, MD, PhD, whose work has helped guide and define the growing array of anticancer immunotherapy drugs, was honored in the Melanoma category with a 2015 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

Geoffrey R. Oxnard, MD, discusses the potential for BRAF-targeting therapies in non-small cell lung cancer.

Experts identify practice-changing or noteworthy abstracts in their field from the research presented at the 2016 ASCO Annual Meeting.

The types of BRAF mutations in non-small cell lung cancer may differ from those observed in melanoma, and a greater understanding of these nuances and their sensitivity to currently available drugs is a central focus of ongoing research.

Even as our understanding of the biology of prostate and bladder cancers improves and treatment protocols are refined, there remain many clinical scenarios in which no clear-cut answers are available.

Suzanne L. Topalian, MD, discusses progress in PD-1/PD-L1 immunotherapies and the prospects for developing biomarkers to better identify patients who would benefit from the new agents.

An ongoing phase II, four-cohort trial involving capmatinib (INC280), an oral MET inhibitor, will determine the clinical activity of the agent in pretreated patients with advanced non-small cell lung cancer who have undergone one or two lines of therapy.

The importance of gaining the input of individual patients with cancer into their own medical management cannot be overstated.

The field of cancer biology is entering a postgenomic era in which most types of human cancer will have been extensively sequenced through efforts such as The Cancer Genome Atlas and the International Cancer Genome Consortium.